Incorporating Angiogenesis Inhibition with Bevacizumab (anti-VEGF) into Frontline Chemotherapy with Irinotecan (CPT-11), Fluorouracil and Leucovorin (FU/LV) for Advanced Colorectal Cancer (advCRC): A Toxicity Analysis of ECOG Study E2200

Reviewer: Thomas Dilling, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 19 de mayo del 2002

Translation for this article does not exist